Prediction of Response to Anti-HER2 Therapy Using A Multigene Assay
Modern Pathology · 2025-04 · 38 (4) · 100713
DOI: 10.1016/j.modpat.2025.100713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2025-04. Verfasst von Nehal Atallah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medical Science, School of Medicine, the University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, United Kin…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Trastuzumab, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Higher Education and Scientific Research.
Abstract (Originalsprache)
HER2-positive breast cancer (BC), which constitutes 13% to 15% of cases, shows variable response to anti-HER2 therapies. HER2 positivity, defined as protein overexpression (immunohistochemistry [IHC] score 3+) or equivocal expression (IHC 2+) with evidence of HER2 gene amplification, determines the eligibility for anti-HER2 therapy. The MammaTyper assay (Cerca Biotech GmbH) is an RT-qPCR BC subtyping platform based on the micro RNA expression of ERBB2, ESR1, PGR, and MKI67. This study aimed to evaluate the accuracy of the MammaTyper assay in predicting the response of HER2-positive patients to therapy. A well-characterized HER2-positive BC cohort of 287 cases diagnosed at Nottingham University hospitals between 2006 and 2018 was included. The cohort was divided into 2 groups: a trastuzumab-treated group (n = 159) and a chemotherapy-only treated group (n = 128). Tumor clinicopathologic characteristics were matched between the 2 groups. Cases with discordant HER2 status were validated through staining of surgical excision specimens. ERBB2 micro RNA identified 251/287 (87.5%) cases as HER2-positive, 10.8% (31/287) as HER2 low and 1.7% (5/287) as HER2 negative. According to the MammaTyper assay, ERBB2-positive patients treated with anti-HER2 therapy had significantly prolonged 5-year disease-free survival and distant metastasis-free survival (hazard ratio = 0.56, P = .003 and hazard ratio = 0.62, P = .023, respectively). MammaTyper-defined HER2-enriched subtype showed a better response to anti-HER2 therapy compared with IHC-defined subtypes, with significant differences in both 5-year disease-free survival and BC-specific survival (P = .01 and .05). Validation analysis revealed that 11/36 ERBB2-negative cases were IHC 2+/ISH positive with very low level of gene amplification and 25 cases were false classified as HER2-positive using current protocols. Combining the MammaTyper assay with IHC to assess HER2 status improves the identification of HER2-positive patients with BC who would benefit from anti-HER2 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Medical Science, School of Medicine, the University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Department of Pathology, Faculty of Medicine, Menoufia Universit…
- Translational Medical Science, School of Medicine, the University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Department of Pathology, Faculty of Medicine, Assiut University,…
- Cerca Biotech, GmbH, Berlin, Germany.
- Translational Medical Science, School of Medicine, the University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Translational Medical Science, School of Veterinary Medicine and…
- Translational Medical Science, School of Medicine, the University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Department of Pathology, Hamad Medical Corporation, Doha, Qatar.…
Förderung
- Ministry of Higher Education and Scientific Research
Zitieren
APA
Atallah, N., Makhlouf, S., Li, X., Zhang, Y., Mongan, N. P., & Rakha, E. (2025). Prediction of Response to Anti-HER2 Therapy Using A Multigene Assay. Modern Pathology, 38(4), 100713. https://doi.org/10.1016/j.modpat.2025.100713
Vancouver
Atallah N, Makhlouf S, Li X, Zhang Y, Mongan NP, Rakha E. Prediction of Response to Anti-HER2 Therapy Using A Multigene Assay. Modern Pathology. 2025;38(4):100713. doi:10.1016/j.modpat.2025.100713
BibTeX
@article{Atallah2025,
author = {Atallah, Nehal and Makhlouf, Shorouk and Li, Xingmin and Zhang, Yuan and Mongan, Nigel P and Rakha, Emad},
title = {Prediction of Response to Anti-HER2 Therapy Using A Multigene Assay},
journal = {Modern Pathology},
year = {2025},
volume = {38},
number = {4},
pages = {100713},
doi = {10.1016/j.modpat.2025.100713}
}
EUVIMED